Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update
K Xu, NC Chan, JW Eikelboom - Expert Opinion on Drug …, 2021 - Taylor & Francis
… dabigatran etexilate, thereby helping to maintain an acid microenvironment. Even then, the
… bioavailability of dabigatran etexilate is only about 6.5%. The dabigatran etexilate prodrug …
… bioavailability of dabigatran etexilate is only about 6.5%. The dabigatran etexilate prodrug …
[PDF][PDF] Secondary stroke prevention in nonvalvular atrial fibrillation
RH Damani, JI Suarez - South Med J, 2016 - researchgate.net
… stroke prevention in NVAF and presents a cost-effectiveness … In 2010, dabigatran etexilate
became the first novel oral an… the FDA for preventing stroke and systemic embolism in patients …
became the first novel oral an… the FDA for preventing stroke and systemic embolism in patients …
Direct oral anticoagulants and venous thromboembolism
M Franchini, PM Mannucci - European respiratory review, 2016 - Eur Respiratory Soc
… inhibitor dabigatran etexilate and the … ], dabigatran was estimated to be cost-effective
compared to warfarin in patients with atrial fibrillation at high risk of stroke, their cost-effectiveness in …
compared to warfarin in patients with atrial fibrillation at high risk of stroke, their cost-effectiveness in …
[HTML][HTML] Health economics of stroke prevention in atrial fibrillation
KL Wang, CE Chiang - Acta Cardiologica Sinica, 2020 - ncbi.nlm.nih.gov
… utilization actually underrates the true cost effectiveness of NOACs, including the … cost-effectiveness
ratio estimates. Finally, the best and most cost-effective strategy of stroke prevention …
ratio estimates. Finally, the best and most cost-effective strategy of stroke prevention …
… outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE …
M Boehm, M Brueckmann, JW Eikelboom… - European heart …, 2020 - academic.oup.com
… This analysis from RELY assessed the risks of death, stroke or systemic emboli, and
bleeding according to mean achieved SBP and DBP in atrial fibrillation on oral anticoagulation. …
bleeding according to mean achieved SBP and DBP in atrial fibrillation on oral anticoagulation. …
Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation
X Yao, NS Abraham, LR Sangaralingham… - Journal of the …, 2016 - Am Heart Assoc
… Using Cox proportional hazards regression, we found that for stroke or systemic embolism,
… ), but dabigatran and rivaroxaban were associated with a similar risk (dabigatran: HR 0.98, 95…
… ), but dabigatran and rivaroxaban were associated with a similar risk (dabigatran: HR 0.98, 95…
Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention
JS Habert - International journal of general medicine, 2016 - Taylor & Francis
… for the prevention of stroke or systemic embolism, Citation17 … for the prevention of ischemic
stroke or systemic embolism (… with a higher number of disabling strokes (82 vs 57 patients), …
stroke or systemic embolism (… with a higher number of disabling strokes (82 vs 57 patients), …
… net monetary benefit of direct oral anticoagulants for the prevention of venous thromboembolism after total knee or hip replacement: A systematic review and meta …
… of evidence from individual cost-effectiveness studies. Crespo … Therefore, we conducted a
systematic review and meta-… the cost-effectiveness of using DOACs for the prevention of VTE in …
systematic review and meta-… the cost-effectiveness of using DOACs for the prevention of VTE in …
Potential cost-effectiveness of ambulatory cardiac rhythm monitoring after cryptogenic stroke
… cost-effectiveness of 30-day ECG monitoring (using an external auto-triggered event loop
recorder) after a cryptogenic stroke or … objectives were to assess the cost-effectiveness of 7-day …
recorder) after a cryptogenic stroke or … objectives were to assess the cost-effectiveness of 7-day …
Cost effectiveness of patient self-managed warfarin compared with direct oral anticoagulants in atrial fibrillation: an economic evaluation in a Danish healthcare sector …
… events, pulmonary embolism, systemic embolism, deep venous thromboembolism, transient
… Daily doses of dabigatran etexilate were 110 or 150 mg, rivaroxaban 15 or 20 mg, and …
… Daily doses of dabigatran etexilate were 110 or 150 mg, rivaroxaban 15 or 20 mg, and …